Johnson & Johnson Consumer Companies, Inc.

Johnson & Johnson Consumer Inc.

Intuit, Inc.

Johnson & Johnson Consumer Products, Inc.

Ethicon, Gmbh

Rutgers, the State University of New Jersey

Mcneil-Ppc, Inc.

Lifescan Corporation

J&j Consumer Companies, Inc.

Reckitt Benckiser Inc.

Enanta Pharmaceuticals, Inc.

Abbvie Bahamas Limited

Ying Sun

Jue-Chen Liu

Jeffrey M Wu

Jonas C T Wang

Stephen J Wisniewski

Ali Fassih

Ralph W Oakeson

James E Hauschild

Lei Pei

Juan Liu

Anna Gosiewska

Jonas C Wang

Yat Sun Or

Dennis D Jamiolkowski

Zhenwei Miao

Nikiforos Kollias

Chunlin Yang

Yie W Chien

Nawaz Ahmad

Dale J Kempf

Zhe Wang

Nick Knudsen

Michael D Southall

Nhung Ho

Aliya Omer

Shun Y Lin

Wei-Min Shi

Ronald J Gillespie

Jeannette Chantalat

Anthony F Coston

Elizabeth S Kimbleton

John Kong-Jiann Li

Ovais Siddiqui

Jyotsna Paturi

Elvin R Lukenbach

Yonghua Gai

Vadim Kraynov

Datong Tang

Joseph B Phipps

Vipul Bhupendra Dave

Jason Pinkstaff

Alexandru Paunescu

Ahmad Y Sheikh

Yi-Lan Wang

Guanghui Zhang

Aruna Nathan

David J Grampovnik

Claude Saliou

Xintian Ming

Hui-Ju J Chen

Ramine Parsa

Wen-Hwa Ting Li

Jason P Shanley

Lillian Skidmore

Suanne Nakajima

Jianzhang Mei

Chong Jin Loy

Susan M Niemiec

Sandra Biroc

Timothy Buss

Brian Porter

Hanuman B Jampani

Carrie H Fang

Michael Joyce

Diana L Friscia

Janet Wangari-Talbot

Devin Garcia

Joseph Junio, Jr

Ya-Ping Hu

Heather Simpson

Melissa Neal

Vivian Zhu

Robin Marsden

Delia Ianina Lopez De Valenta

Yiyin Ku

Tim Grieme

Marisa DeVita Dufort

Abla A Creasey

Ruobing Lu

Anne-Sophie Brillouet

Gouyou Xu

Dianne Rossetti

Elizabeth Kimbleton

Robert Wayne Yates

Elisabeth S Kimbleton

Anna Prilutsky

Jennifer Hagyoung Kang Choi

Joan D Newburger

Keith F Mcdaniel

Dong Liu

Stefanie A Johnsen

Feng Tian

Ken Engstrom

Sable H Wagaw

Marco Gymnopoulos

Anna-Maria A Putnam

Kyle C Atkinson

Angieszka Szydlik

Heather Elizabeth Simpson

Andrew Beck

A method may include executing a baseline classifier on unreviewed transaction features of an unreviewed transaction record to obtain a baseline account identifier, and executing a comparison model on (i) an unreviewed transaction vector of the unreviewed transaction record and (ii) reviewed transaction vectors to obtain comparison scores. The reviewed transaction vectors may correspond to reviewed transaction records each having a user-approved account identifier. The method may further include selecting, using the comparison scores, a reviewed transaction record. The reviewed transaction record may correspond to a comparison score. The comparison score may correspond to a user-approved account identifier of the reviewed transaction record. The method may further include selecting, using the comparison score, one of the baseline account identifier and the user-approved account identifier to obtain a selected account identifier, and presenting the selected account identifier for the unreviewed transaction record.

Learning user actions to improve transaction categorization

A method utilizes a framework for transaction categorization personalization. A transaction record is received. a baseline model is selected from a plurality of machine learning models. An account identifier, corresponding to the transaction record using the baseline model, is selected. The account identifier for the transaction record is presented.

Framework for transaction categorization personalization

A method performs personalized transaction categorization. A transaction record is received, by a server application. In a first stage, sparse raw features are extracted from a transaction record of a transaction and converted into a transaction vector including dense features. In a second stage, the transaction vector is classified into a customized chart of accounts using the dense features to generate adapter model output. The method further includes selecting, an account identifier, corresponding to the transaction record and to an account of the customized chart of accounts, using the adapter model output, and presenting the account identifier for the transaction record.

Personalized transaction categorization

The present invention relates to devices and methods for treating, reducing and preventing adverse skin/scalp conditions and enhancing the topical application of a benefit agent. The devices are ultrasonic with transducers positioned at an angle other than 90&#xb0; relative to the surface at which the ultrasound is to be applied.

Devices and methods for enhancing the topical application of a benefit agent

Low pH compositions for topical administration to skin are provided. They comprise a buffering agent having a pKa of about 2.8 to about 4.2 and a cosmetically acceptable active ingredient having a pKa within about 1 unit of the pKa of the buffering agent. The composition has a pH of about 3.3 to 4 and a buffer capacity of at least about 0.15. A method of increasing the topical delivery of a cosmetically acceptable active ingredient having a pKa of about 2.8 to about 4 is also provided.

Topical delivery of skin compositions having low pH

A composition comprising: a benefit agent; at least one polymer including a polycaprolactone polymer; at least one lower alcohol; and at least one co-solvent; and a method for enhancing topical delivery of a benefit agent is disclosed.

Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent

A powder is disclosed including a first powder of core/shell particles having an average particle size of less than 1000 microns, each particle contains a liquid core that is substantially free of water that includes a polar liquid having a percent surface polarity of at least 24%; and a shell comprising hydrophobic particles and a second powder including a color cosmetic.

Compositions and methods for enhancing the topical application of a color cosmetic

A composition comprising: a benefit agent; at least one polymer including a poly(monostearoyl glycerol-co-succinate) polymer; at least one lower alcohol; and at least one co-solvent; and a method for enhancing topical delivery of a benefit agent are disclosed.

Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent

A powder is disclosed including core/shell particles having an average particle size of less than 1000 microns, each particle contains a liquid core that is substantially free of water and includes A) a polar liquid having a percent surface polarity of at least 24%, a basic active ingredient, and C) from about 0.1% to about 20% by weight of at least one acidic solubility enhancing agent that is not an active ingredient; and a shell comprising hydrophobic particles. The powder can be used to topically administer the active ingredient to a human or animal.

Compostions and methods for enhancing the topical application of a basic benefit agent

A powder is disclosed including core/shell particles having an average particle size of less than 1000 microns, each particle contains a liquid core that is substantially free of water and includes A) a polar liquid having a percent surface polarity of at least 24%, an active ingredient, and C) from about 0.1% to about 20% by weight of at least one solubility enhancing agent that is not an active ingredient; and a shell comprising hydrophobic particles. The powder can be used to topically administer the active ingredient to a human or animal.

Compostions and methods for enhancing the topical application of an acidic benefit agent

The present invention features a device having a barrier membrane contacting surface, the device containing: a power source; a first conductive electrode; a second conductive electrode; and a reservoir; wherein said power source is in electric communication with said first conductive electrode and said second conductive electrode, wherein said first conductive electrode and said second conductive electrode are arranged such that they are both capable of being in ionic communication with a carrier upon the inclusion of said carrier to said reservoir; and the use thereof.

Device for treatment of a barrier membrane

Implantable medical devices having galvanic particulates are disclosed. The particulate may be coated onto at least part of a surface of the medical device. In addition, the galvanic particulates may be contained in the material used to manufacture the antimicrobial medical devices, or may be embedded into the surface of the medical devices. The present invention also provides novel coating methods and processing methods. The present invention further provides a combination of galvanic particulates with an aqueous gel, a method of making this combination, and a method of treatment using this combination. The devices and compositions may have advantageous characteristics and effects including anti-microbial, anti-inflammatory, tissue regeneration promoting, and pain reduction or elimination.

Medical devices with galvanic particulates

The present invention is directed to a hemostatic material comprising a scaffold and a galvanic particulate. The galvanic particulate comprises particles made of at least two dissimilar metals. The scaffold is preferably a biocompatible polysaccharide-based hemostatic, such as a chitosan or cellulosic based hemostatic like ORC.

Hemostatic materials and devices with galvanic particulates

Growing community of inventors

Belle Mead, NJ, United States of America

Ying Sun